Skip to main content
. 2020 Feb 12;21:50. doi: 10.1186/s12931-020-1310-9

Fig. 4.

Fig. 4

Panel (a) Change in FEV1 and FVC after 4 weeks of oral prednisolone (30 mg/day) in female non-smoking COPD patients (open bars) or placebo (black bars); data are mean values ± SEM; NS = non-significant; Panel (b) Decline in post-bronchodilator FEV1 between healthy (n = 88), smoking COPD (n = 44) and non-smoking COPD subjects (n = 62) over 2 years